ArticleView (Beijing, China)2026
PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.
Article in View (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Impact of PSMA PET Fusion-Based RT Planning on Dosimetry and PSA Response in Prostate Cancer.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Positron emission tomography (PET), particularly with prostate-specific membrane antigen (PSMA) tracers, has revolutionized the clinical management of prostate cancer (PCa). This review highlights the pivotal role of PET molecular imaging in guiding radiotherapy (RT) across diverse clinical scenarios, from postoperative biochemical recurrence to oligometastatic disease. Growing evidence shows that PET excels in lesion detection, enhances target volume delineation, enables focal dose escalation, and guides treatment intensification. PSMA PET increases the precision of RT planning, supports personalized therapeutic approaches, and is associated with improved outcomes, including biochemical recurrence-free and metastasis-free survival. The integration of PET with advanced RT technologies, including biology-guided radiotherapy (BgRT), is paving the way for real-time, biologically adaptive treatment paradigms. However, challenges remain, including the need for standardized protocols, management of tracer variability, and clinical translation of innovations such as PET-linear accelerator (LINAC) into routine practice. Future research should prioritize large-scale, prospective studies to establish the clinical efficacy, cost-effectiveness, and optimal integration of PET-guided RT in PCa care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.